BIOGENA • Investment story • Direct digital investment

BIOGENA investment story

A family business becomes a health group. What began for BIOGENA as a family-run micronutrient company is today a health group with more than 120 million euros in revenue.

Since 2015, many investors have accompanied this journey through Invesdor. Since then, BIOGENA has carried out 16 financing rounds via Invesdor. In total, more than 17 million euros in growth capital flowed into the company. BIOGENA is now carrying out a share issue and preparing for a listing on the Direct Market Plus (Vienna MTF) of the Vienna Stock Exchange. This makes BIOGENA an example of direct digital investment in a real company that has developed step by step and is now entering the capital market.

Direct digital investment: the role of Invesdor investors

Between 2015 and 2022, BIOGENA carried out a total of 16 financing rounds via Invesdor. During this period, investors provided more than 17 million euros in growth capital through Invesdor.

This path is characterized by:

1

Long-term partnership

BIOGENA did not choose this form of financing only once, but repeatedly, adapted to each respective growth phase.

2

Direct participation for many instead of a few

Private and smaller professional investors were able to participate at an early stage, with amounts suited to their personal situation. Over the years, this created a broad circle of supporters.

3

Strong European roots

A significant share of the investments came from Germany, Austria and other European countries — the same markets in which BIOGENA is also gaining customers. Since 2015, around 2,100 investors have invested in BIOGENA through Invesdor. On average, investments amounted to around 7,300 euros per person. Depending on the round, the interest rates of the individual bonds ranged from 3.75% to 6.00% per year. All investments were repaid to investors on schedule and in full.

For many people in Germany, Austria and other European countries, BIOGENA therefore offered an opportunity to participate directly in a medium-sized health company and follow its development over several years.

What BIOGENA has achieved so far

The capital market prospectus for the current share issue describes BIOGENA’s starting position with clear figures. For the 2024/2025 financial year, the Biogena Group reports, among other things:

• group revenue of around 124.9 million euros
• historical EBITDA of around 19.1 million euros
• an EBITDA margin of around 15.3 percent
• group equity of around 298.9 million euros

BIOGENA offers more than 400 products and works with around 30,000 doctors and therapists. The company serves customers in around 70 countries and has more than half a million registered members in the BIOGENA Club. According to the prospectus, BIOGENA already has a production capacity built for revenues of around €500 million, which is currently only partially utilized. These figures and structures show an established company with audited financial statements, international reach and a clear focus on prevention and health.

Why the step onto the stock exchange is a logical one

Against this background, the planned step onto the stock exchange is a logical next step for BIOGENA. An IPO enables further equity capital for growth, for example for internationalization, product development, digitalization and new locations.

It creates additional visibility and trust in a regulated environment.

It enables a broader distribution of ownership, into which existing investors can also place themselves as part of their own decisions. For many years, BIOGENA relied on direct financing via Invesdor. This phase helped expand the production capacity, broaden the market and strengthen digital channels. The now planned listing on Direct Market Plus of the Vienna Stock Exchange adds the capital market level to this path.

Context for investors

What investors gain from this now

For people who have already financed BIOGENA through Invesdor, the current development is an important milestone. They can see that a family business has become a health group with revenue well above 120 million euros. All BIOGENA investments placed via Invesdor were repaid as agreed.

• The company has reached a stage where a stock exchange listing can be carried out.

For investors who are only now getting to know BIOGENA, a different perspective emerges: this is a company with a clear market position and tangible products.

• The development of recent years and the current situation are presented transparently in the prospectus.

In both cases, the share issue opens up the opportunity to assess whether and in what form participation in the next stage of the BIOGENA story fits into one’s own investment concept. All information on the current share issue, the use of proceeds and the risks can be found in the capital market prospectus and on BIOGENA’s information page.

Current share issue

Further information on the current BIOGENA share issue

All information on the current share issue, the documents and further details can be found directly on BIOGENA’s information page.

To the BIOGENA share issue

The link opens BIOGENA’s information page in a new tab.

Notes and risks

This text provides information about BIOGENA’s development and the role of Invesdor investors. It does not constitute investment advice and is not an invitation to buy or sell securities. Invesdor does not provide investment brokerage in this context.

The basis for an investment decision is exclusively the published capital market prospectus and the documents of the issuer. Investments in securities and corporate participations involve significant risks, including the complete loss of the capital invested.

The post How Direct Digital Investing can pave the way to the Stock Market first appeared on Invesdor - Blog.

This is where Liion Power comes in. The clean tech company from Amsterdam develops intelligent charging technologies that significantly extend battery life. 

Its first product, Leo, is a smart plug-and-play USB charger. It charges batteries gently and based on data. Building on this, a scalable software and data platform for electronics manufacturers and e-mobility providers is being developed. 

Liion Power’s goal: extend the usable life of devices while reducing environmental impact, conserving resources, and lowering costs. 

For investors, Liion Power is an exciting opportunity in the fields of energy efficiency, battery technology, and recurring software revenue. 

When batteries die too soon: the environmental impact 

What happens when a battery starts to weaken? It often doesn’t stop with a battery swap. In many cases, the entire device ends up sitting in a drawer for years or goes straight to the trash. The consequences?  

• Increasing amounts of electronic waste 
• High demand for new batteries – and thus raw materials 
• Additional CO₂ emissions from production, transport, and disposal 
• Extra costs for new devices  

The use of lithium-ion batteries is on the rise. They’re found in consumer electronics, e-bikes, e-scooters, tools, and a wide range of connected devices. Global forecasts predict the lithium-ion battery market will reach hundreds of billions by 2030. 

At the same time, the segment for smart charging and battery management solutions is seeing strong annual growth. 

Regulation is also tightening. New EU rules demand greater transparency around battery life and sustainability. Manufacturers must show how durable their products are and how responsibly they manage resources. 

The key question: how can existing battery capacity be better used before producing new cells? 

Liion Power turns simple charging into intelligent battery solutions 

Liion Power was founded in 2021 with the mission to extend battery usability. The approach: don’t just monitor charging – actively manage it.  

Leo: smart plug-and-play charging 

Leo is a device that fits via USB between the power adapter and your device. It extends battery life by: 

• Analyzing the battery of the connected device 
• Adjusting charging limits and speed 
• Planning short charging pauses 
• Reducing stress from fast charging, 100% charging, overnight charging, and preventing high temperatures 

Tests show Leo can increase battery life by up to 63%. Around 4,900 Leo units have been sold across 59 countries. Preorders worth approximately €250,000 confirm market demand. 

Leo is both a product and a data source. Every use provides anonymized insights into real-life charging and battery use.  

From hardware to B2B software platform 

Based on this foundation, Liion Power is developing its technology into a B2B software licensing platform.  

The concept: 

• Liion Power’s algorithms and embedded firmware are integrated directly into manufacturers’ products – such as chargers, e-bikes, headphones, routers, or other IoT devices. 
• Manufacturers can gently charge batteries in their devices, offer customers longer usage times, and improve their sustainability metrics. 
• Liion Power earns revenue through licensing and SaaS models, e.g., per device and per connected system. 

This allows the company to grow from a hardware vendor into a software and data company focused on battery health and energy efficiency. . 

Extended battery life: real-world benefits for users and businesses 

What does smart charging offer in daily life and business operations? The benefits are visible on multiple levels.  

1. Longer use instead of early replacement 

Gentler charging extends battery lifespan. For end users, this means: 

• Devices need to be replaced less often 
• Spending on new hardware decreases 
• Battery issues appear later in the device lifecycle 

For businesses – like e-bike or e-scooter fleet operators – key benefits include: 

• Longer service life of vehicles 
• Less need for battery or device replacements 
• Lower maintenance and service costs  

The simple question is: how many extra years of use can be gained from a battery that’s actively protected?  

2. Less e-waste and lower CO₂ emissions 

If batteries last longer, fewer new ones need to be made. This reduces both e-waste and CO₂ emissions. 

Liion Power estimates that extending battery life by around 50% can save 20 to 30 kg of CO₂ per device. In households with 8 to 10 rechargeable devices, this adds up to 160 to 300 kg of CO₂ savings per household. 

With integration into millions of devices, the emission reduction in the electronics sector becomes significant.  

3. Improved sustainability metrics for manufacturers

Manufacturers face growing pressure to make products more durable and resource-efficient. Consumers and regulators increasingly care about how long devices last. By integrating Liion Power’s software, manufacturers can: 

• Demonstrably extend product life 
• Back up sustainability reports with real data 
• Strengthen their profile as providers of durable and efficient tech  

This helps meet requirements around battery passports, circular economy, and reporting. 

4. Transparency and data-driven decisions 

In the consumer market, users gain insights into battery status and charging behavior via an app. They can see what’s stressing the battery and how its lifespan is developing. 

In business settings, fleet operators and OEMs use dashboards to:  

• Monitor battery health in the field 
• Plan maintenance 
• Reduce failures 

The collected data flows back into the algorithms – improving accuracy with each use. 

From charger to data platform: why smart battery tech and Liion Power matter to investors 

What makes Liion Power interesting is the combination of real-world value and a scalable business model.  

1. A growing sector around lithium-ion batteries 

Lithium-ion batteries are a key technology in the modern economy. As electric mobility, connected devices, and portable electronics become more widespread, so does the need for battery health solutions. 

Liion Power targets the segment where batteries age prematurely due to poor charging. This affects countless existing and future applications – opening up wide potential for smart charging technology. 

2. Dual approach with hardware and software

Liion Power combines two layers: 

• Hardware revenue from Leo in the consumer segment 
• Software and licensing revenue in the B2B segment 

In the short term, Leo builds visibility, customer feedback, and real-world data. In the medium to long term, software licenses and SaaS models offer high margins and international scalability. 

Typical license models include fees per device plus ongoing charges per connected unit, along with integration and support services. 

3. Data as part of the company’s value

Liion Power’s technology collects charging and usage data from real applications. These data: 

• Improve the algorithms 
• Demonstrate value to OEMs and fleet operators 
• Provide an edge over competitors without equivalent data 

This makes data a key value driver for the company. 

4. Strategic partners and experienced shareholders 

Liion Power collaborates with partners such as Init Power and TOP-electronics. TOP-electronics provides access to numerous OEMs in Europe, the US, and Asia – helping integrate the software into existing supply chains. 

The shareholder base includes founders with physics, tech, and entrepreneurial expertise, as well as investors experienced in finance, electronics, and sustainable tech. The founders retain majority voting rights and are committed to long-term value growth. 

5. Impact investing with measurable outcomes 

Liion Power contributes to multiple UN Sustainable Development Goals, including industry, innovation, responsible consumption, and climate action. 

The impact is quantifiable: saved CO₂ emissions, reduced e-waste, and longer product lifespans. For impact-driven investors who want measurable results, this is a strong value proposition. 

6. Potential exit opportunities

As the technology spreads, several exit paths emerge, such as: 

• Acquisition by a player in electronics, battery tech, or e-mobility 
• Sale of technology and IP to a larger industry partner 
• A potential IPO, provided recurring software revenues and international integration scale accordingly 

All scenarios share one thing: the value of Liion Power’s tech and data grows with usage. 

Conclusion: Liion Power in the cleantech market – why it’s worth a closer look 

Liion Power brings several trends together. The technology behind Leo is tested and already on the market. The B2B software platform builds on it and creates the foundation for recurring license and data revenues. The demand for longer-lasting batteries is increasing. Regulation and consumer expectations support solutions that extend product life and conserve resources. 

For those looking to invest in companies tackling clear problems with concrete tech solutions and scalable models, Liion Power offers a compelling, transparent proposition. 

The key question for investors: what role will smart charging play in a world where more and more devices are electric and connected? Liion Power offers an answer that aligns with exactly that development. 

Learn more and invest in smart battery technology now 

Visit the Liion Power investment page 

Disclaimer: Please read the risk disclosures and documents carefully. Investments in securities of growth companies can result in the total loss of invested capital. 

The post Liion Power: smart charging to prevent premature battery death and extend battery life  first appeared on Invesdor - Blog.

PCaVision offers a new way to make diagnostics more efficient, faster, and accessible. The Dutch MedTech company is developing an AI-powered prostate cancer diagnostic tool based on ultrasound, enabling urologists to make a diagnosis in a single session —without MRI and without radiologists. 

In doing so, PCaVision addresses a care gap that is only set to grow in the coming years. That’s why this project is also compelling for investors: it combines medical benefit, impact investing in healthcare, and a scalable SaaS model with strong growth potential.  

Prostate cancer – an urgent health challenge  

A common disease. A diagnosis that takes time and energy. 

Prostate cancer is one of the most frequently diagnosed cancers in men. Global demand for diagnostic procedures is growing by about 10% each year. By 2040, demand is expected to double. Reasons include: 

• An aging population 
• Expanded preventive care programs 
• Growing awareness of prostate cancer screening 

1. Waiting for the exam – often for weeks 

Suspected prostate cancer is stressful. Many patients wait weeks for an MRI appointment due to limited radiology capacity. This creates uncertainty and delays potential treatment.

2. Multiple appointments, more effort

DThe standard process looks like this: 

• Suspicion raised during a urologist visit

• Referral for MRI 

• MRI result from a radiologist 

• Follow-up with the urologist 

• Targeted biopsy 

The result: delays, extra steps, and numerous appointments. 

3.Invasive procedures, often unnecessary 

The alternative to MRI is a systematic biopsy involving multiple tissue samples—even if no clinically relevant cancer is found. This places a physical and mental burden on patients.

4. Capacity issues across the system

Urology and radiology departments are already stretched thin. Overloaded diagnostic structures mean longer wait times  and case numbers continue to rise. 

In short: the system is reaching its limits, and the ones suffering are the men who need clarity. 

PCaVision streamlines the lengthy diagnostic process

PCaVision accelerates diagnosis by combining AI and ultrasound. The technology is clinically validated, CE-certified, and already in use in pilot clinics. 

How does it work in practice?

• The urologist uses a standard 3D/4D ultrasound probe
• PCaVision analyzes the data automatically
• The software generates a color-coded heatmap highlighting suspicious areas

The physician can perform targeted biopsies in the same session

A diagnostic process that used to take weeks is now completed in just 20–30 minutes.  

Benefits for patients: clearer, less stressful, faster diagnosis  

1. Faster diagnosis enables earlier treatment
Many men spend weeks in uncertainty. PCaVision drastically reduces this time. Early, clear diagnoses improve the chances of detecting cancer at a treatable stage.

2. Less physical strain
Targeted biopsies instead of “blind” sampling mean: 

• Fewer punctures
• The physician can perform targeted biopsies in the same session
• Less post-procedure discomfort

Studies show unnecessary biopsies can be reduced by up to 75%. 

3. No additional appointments, everything in one session 
Patients no longer need to wait for MRI slots, organize travel to radiology centers, or coordinate multiple doctor visits. This saves time, reduces stress, and makes the process more predictable. 

4. MRI-level diagnostic quality, but more accessible 
PCaVision matches MRI in detecting clinically relevant tumors, but it’s significantly more affordable and can be used wherever ultrasound is available. 

5. Greater equity in access to care 
In many regions, MRI access is limited. This technology enables diagnostics in places where patients previously faced long waits. For men in rural or underserved areas, that’s a real advantage. 

In short: PCaVision gives patients earlier clarity, reduces their burden, improves access to diagnostics and relieves the pressure on the healthcare system. 

Why this matters to investors 

Because patient benefits are directly tied to economic potential. The bigger the medical problem, the stronger the market and the clearer the need for a better solution. 

1. A large, growing market 
Over 10 million diagnostic procedures globally each year 
Growth: ~10% annually 
By 2040: expected to double 

This is a huge market, and PCaVision addresses a critical bottleneck. 

2. A solution that truly relieves the system 
The technology shortens diagnostic times from weeks to minutes. That means real capacity gains, cost reduction, and higher efficiency. 

For clinics, that translates to: 

• Faster workflows 
• Less dependency on MRI 
• Economic benefits 

A product that cuts costs while improving care quality has strong chances for widespread adoption. 

3. A scalable SaaS business model 
PCaVision earns per scan, not per device. That means: 

• Recurring revenue 
• Predictable income 
• High margins 
• Low variable costs 
• Strong scalability 

Every clinic becomes a long-term revenue driver. 

4. Clinically validated, CE-certified, early customers onboard 
The company is no longer a research project, it’s a product in the market. This maturity reduces tech risk for investors. 

5. Strong institutional backers 
The Series A is supported by: 

• NLC Health Impact Fund 
• CbusineZ 
• TU/e Holding
• Family offices and experienced angel investors 

Private investors participate via Invesdor on the same preferred share terms as these institutional investors, meaning equal economic rights. 

6. Impact investing with measurable value 
This healthcare technology: 

• Speeds up diagnoses 
• Reduces unnecessary procedures
• Improves access to care  
• Relieves pressure on healthcare systems 

… fulfilling SDG 3: “Good Health and Well-being.” 

Investing in PCaVision means tackling a socially relevant problem, with potential for financial upside.

7. Attractive exit options in MedTech 
MedTech companies with strong clinical evidence and scalable models are frequently acquired. Potential outcomes include: 

• Strategic acquisition by imaging or diagnostics giants 
• Series B funding at a higher valuation
• Regional licensing or distribution partnerships 

As market adoption grows, so does company value and investor potential. 

What matters:

Investing in growth companies carries risk, including total loss. 
At the same time, this market often offers a compelling risk-reward ratio. 

A rational checklist: 

• Is the market big enough? → Yes: growing, driven by demographics and medical need 

• Does the company solve a real problem? → Yes: a genuine and growing care gap 

• Is the product validated and market-ready? → Yes: CE-certified, early clinics onboard, strong data 

• Is the business model scalable? → Yes: SaaS with recurring revenue 

• Are experienced investors involved? → Yes: institutional and strategic partners 

For many investors, PCaVision is compelling: it combines medical value, measurable impact, and a scalable tech model, a rare combination in the MedTech space. 

Conclusion: why now may be the right time 

PCaVision is at the intersection of technology, market, and timing. The clinical evidence is strong, early adopters are in place, the product is ready and the healthcare problem is only growing. 

Those looking to invest in companies that: 

• Drive medical progress 

• Address real care gaps 

• Offer clear growth potential 

… will find in PCaVision a project with clear relevance and solid foundations. 

Find out more now and invest in MedTech: your opportunity to help shape the future! 

Visit PCaVision’s investment page 

Disclaimer: Please read the risk disclosures and documentation carefully. Investing in securities of growth companies can result in a total loss of invested capital.

The post Detect prostate cancer earlier: How PCaVision helps patients and appeals to investors  first appeared on Invesdor - Blog.

Max, you founded Beets & Roots in 2016 together with star chef Andi Tuffentsammer. You offer healthy bowls, salads, wraps and high-quality soups in your restaurants and via online ordering. You first financed your growth via crowdfunding on Invesdor in 2019, and you are now in your fourth crowdfunding round. How did you get into crowdfunding? 

At that time, we only had our first three restaurants in Berlin and wanted to expand further. With our ordering system via the internet, we had a real boom phase at the time and wanted to expand that further. We used the capital to open more restaurants. In the meantime, the investors have received their 750,000 euros back, along with 8.5 per cent interest per year and a one-time profit interest of 5 per cent. So it was a complete success for us and for the investors.

Your second funding campaign was then in October 2021, in the middle of a peak phase of the pandemic. Wasn’t that risky?

Corona was like a dark shadow over us at the time. But we wanted to continue the growth course and reach more customers with our own app, among other things, despite the pandemic. It was important for us to become a mobile-first company in the next step, and we made up for it. In addition, we want to take customers and investors along on our journey to climate neutrality 2025, which we had set as a goal. Our products, the brand and our target group fit very well with the theme of sustainability. That’s why we designed the second campaign differently.

What did you do differently from the first time?

This time we did not pay interest on a subordinated loan from our investors, but issued 16,000 shares in our company as participation rights, which corresponds to 8.7 percent in our company. In return, the basic interest rate was lower at 5.0 percent. With the participation rights, we offered investors a new participation model, especially since we tokenised the shares, i.e. issued them digitally. This allows investors to participate in the increase of the company’s value. We were among the first in Germany to choose this path.

Was that well received?

Yes, after only 22 days we had the 1.1 million euros together. The goal of this financing round was to also expand nationwide with restaurants in Stuttgart, Frankfurt am Main and Düsseldorf.

In 2022, a third round of financing for 537,000 euros took place. Did you take the big leap after the Corona pandemic? 

That’s one way to put it. In the third crowdfunding round, the main focus was on financing our new high-frequency locations in Berlin at Potsdamer Platz, at the main railway station and at BER airport. Here, too, crowdfunding was the best fit because we had already won the leases and were able to appeal to the travel industry at the same time. For investors, this was an interesting investment opportunity. We always finance everything in a mix, which means we financed both equity and mezzanine capital via the crowd. In terms of marketing, we focused less on the retail investor and more on the semi-institutional investor.

You also joined a large family office, which brought you 2.7 million euros for 18.5 percent of the company shares. Why did you turn to the professional investor?

For us, it is important to create stable growth, and for that we need a stable financing structure with substantial equity. That’s why we didn’t want to focus everything on the crowd, especially in uncertain times where the equity cushion always plays a big role. We need strong partners, we need a strong equity ratio. That is also in the interest of the crowd. 

Is this participation of a family office directly linked to distributions or does it only rely on an increase in the value of the company?

There are no distributions, we are a growth company and reinvest our cash flow in our growth projects. This is also comprehensible for all existing shareholders and crowd investors. No one has to fear that any shareholders will be served from crowdfunding funds.

How is the fourth crowdfunding round offer constructed?

In terms of company law, it is the same as the first and third rounds, so it is a subordinated loan. But because of the increased interest rate environment, we have also increased the interest rate to 10 per cent. In addition, a one-off success interest of another 10 per cent is possible. The financing costs have risen for us, as they have for all companies, which is why we now have to offer investors a higher return.

What sum are you aiming for and what do you intend to do with it?

For example, we currently have the second contract with Deutsche Bahn in the pipeline for Ostbahnhof, where we would like to open a restaurant. We are hoping for investor money between 500,000 and one million euros. We would also like to use the money to expand the licence business. We already have two licensed stores with partners, for example in Frankfurt. We want to grow in the markets outside of Berlin primarily with licence partners, simply because it enables operational stability and faster growth.

Where does beets & roots stand today, how has the business developed?

We now have 14 restaurants in five major cities. In 2022, we had a turnover of 7.2 million euros including the licence partners. For 2023, we expect a turnover of around 11 million euros. We also have initial cooperations with Rewe and Edeka, which resell our bowls from the freezer. The delivery services Flink and Gorillas have also included our dishes in their range. The desire for healthy, sustainable gastronomy is huge.

You have remained loyal to Invesdor as a crowdfunding platform for your campaigns. What are the advantages for you? Why did you choose Invesdor?  

At the end of the day, what counts for us is the relationship of trust, which also comes from our circle of shareholders. From the first to the fourth campaign, the cooperation with Invesdor has been characterised by a high level of professionalism. That gives us a very good feeling. After all, we also enter into liabilities with this form of financing and want everything to be based on the highest legal and social standards, both for the investors and for us. Invesdor guarantees that.

Another huge plus is the flexibility and simplicity. Existing banks are more cumbersome in the financing process than a modern, digitalised partner like Invesdor.  In addition, Invesdor itself is a growth story and has continued to expand through mergers and continuous improvements to the platform and investor experience. This shows us that we are betting on the right partner.

So further crowd campaigns with Invesdor are not out of the question?

Absolutely not! The bigger we get, the bigger the funding pots get, and the mix can certainly change in some way. But the crowd always plays a big role for us. As long as it works for us and for the investors, we want to continue the cooperation.

The post Interview with Max Kochen from beets & roots first appeared on Invesdor - Blog.